In the late 1980s, shortly after he left the NIH, Dr Martin B Leon founded the non-profit organisation, Cardiovascular Research Foundation (CRF). At the beginning, CRF had almost no funding or people, but it had a concept of bringing together an academic community to follow the device development cycle from inception to inclusion. Today, CFR is a global entity, and its events are attended by hundreds of physicians/researchers worldwide.
In the Season 2 finale, Ankur Kalra is joined by the legendary Martin B Leon, Professor at Columbia University, director of the Transcatheter Cardiovascular Therapeutics and chairman emeritus of the CRF.
In this in-depth discussion Dr Leon talks about what he believes is behind the success of CRF and the lessons he learnt from disappointments and mistakes along the way. Dr Leon stresses the importance of collaborations on a global scale. He talks about his plans for the future and the issues that were highlighted by the events of 2020. Ankur asks Dr Leon about his role as a mentor and about the qualities he is looking for in a mentee.
What makes Dr Martin B Leon tick? What is his message to cardiologists and/or researchers at the beginning of their careers? How did the pandemic and his work as a clinician in New York change his perspective?
Hosted by @AnkurKalraMD.
Produced by @RadcliffeCARDIO. Submit your questions to Ankur via: podcast@radcliffe-group.com.
Sponsored by Edwards.
Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.